Brief: Invivyd Announces Results From 180-Day Exploratory Efficacy Analysis Of CANOPY Phase 3 Study
27/08/2024 12:00
Aug 27 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD: RESULTS FROM 180-DAY EXPLORATORY EFFICACY
ANALYSIS OF
CANOPY PHASE 3 STUDY
* INVIVYD: IN IMMUNOCOMPROMISED PATIENT ARM OF STUDY,
PEMIVIBART
SHOWED 3.7% OF PARTICIPANTS CONTRACTING COVID, HOSPITALIZATION &
DEATH
* INVIVYD: PEMIVIBART SHOWED 84% RELATIVE RISK REDUCTION
VERSUS
PLACEBO IN COVID-19 CASES WHERE DIAGNOSIS WAS CONFIRMED THROUGH
RT-PCR TEST
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview